168 related articles for article (PubMed ID: 1400423)
1. Conveyance of partial agonism/antagonism to bombesin/gastrin-releasing peptide analogues on Swiss 3T3 cells by a carboxyl-terminal leucine insertion.
Kull FC; Leban JJ; Landavazo A; Stewart KD; Stockstill B; McDermed JD
J Biol Chem; 1992 Oct; 267(29):21132-8. PubMed ID: 1400423
[TBL] [Abstract][Full Text] [Related]
2. Development of potent gastrin-releasing peptide antagonists having a D-Pro-psi(CH2NH)-Phe-NH2 C terminus.
Leban JJ; Kull FC; Landavazo A; Stockstill B; McDermed JD
Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1922-6. PubMed ID: 8446610
[TBL] [Abstract][Full Text] [Related]
3. Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi.
Radulovic S; Cai RZ; Serfozo P; Groot K; Redding TW; Pinski J; Schally AV
Int J Pept Protein Res; 1991 Dec; 38(6):593-600. PubMed ID: 1726427
[TBL] [Abstract][Full Text] [Related]
4. Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity.
Coy DH; Taylor JE; Jiang NY; Kim SH; Wang LH; Huang SC; Moreau JP; Gardner JD; Jensen RT
J Biol Chem; 1989 Sep; 264(25):14691-7. PubMed ID: 2475489
[TBL] [Abstract][Full Text] [Related]
5. Chronic desensitization to bombesin by progressive down-regulation of bombesin receptors in Swiss 3T3 cells. Distinction from acute desensitization.
Millar JB; Rozengurt E
J Biol Chem; 1990 Jul; 265(20):12052-8. PubMed ID: 2164025
[TBL] [Abstract][Full Text] [Related]
6. [Leu13-psi(CH2NH)Leu14]bombesin is a specific bombesin receptor antagonist in Swiss 3T3 cells.
Woll PJ; Coy DH; Rozengurt E
Biochem Biophys Res Commun; 1988 Aug; 155(1):359-65. PubMed ID: 2843183
[TBL] [Abstract][Full Text] [Related]
7. Covalently cyclized agonist and antagonist analogues of bombesin and related peptides.
Coy DH; Jiang NY; Kim SH; Moreau JP; Lin JT; Frucht H; Qian JM; Wang LW; Jensen RT
J Biol Chem; 1991 Sep; 266(25):16441-7. PubMed ID: 1715866
[TBL] [Abstract][Full Text] [Related]
8. Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats.
Pinski J; Yano T; Groot K; Cai RZ; Radulovic S; Schally AV
Am J Physiol; 1992 Oct; 263(4 Pt 1):E712-7. PubMed ID: 1415689
[TBL] [Abstract][Full Text] [Related]
9. Bombesin receptors in a human duodenal tumor cell line: binding properties and function.
Williams BY; Schonbrunn A
Cancer Res; 1994 Feb; 54(3):818-24. PubMed ID: 8306345
[TBL] [Abstract][Full Text] [Related]
10. Effects of BIM26226, a potent and specific bombesin receptor antagonist, on amylase release and binding of bombesin-like peptides to AR4-2J cells.
Dietrich JB; Hildebrand P; Jeker LB; Pansky A; Eberle AN; Beglinger C
Regul Pept; 1994 Oct; 53(3):165-73. PubMed ID: 7531356
[TBL] [Abstract][Full Text] [Related]
11. A potent bombesin receptor antagonist inhibits bombesin-stimulated growth of mouse colon cancer cells in vitro: absence of autocrine effects.
Narayan S; Spindel ER; Rubin NH; Singh P
Cell Growth Differ; 1992 Feb; 3(2):111-8. PubMed ID: 1323998
[TBL] [Abstract][Full Text] [Related]
12. Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi.
Cai RZ; Radulovic S; Pinski J; Nagy A; Redding TW; Olsen DB; Schally AV
Peptides; 1992; 13(2):267-71. PubMed ID: 1409006
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of peptide and pseudopeptide amides inhibiting the proliferation of small cell and epithelial types of lung carcinoma cells.
Nyéki O; Rill A; Schon I; Orosz A; Schrett J; Bartha L; Nagy J
J Pept Sci; 1998 Dec; 4(8):486-95. PubMed ID: 9927255
[TBL] [Abstract][Full Text] [Related]
14. Peptide structural requirements for antagonism differ between the two mammalian bombesin receptor subtypes.
Lin JT; Coy DH; Mantey SA; Jensen RT
J Pharmacol Exp Ther; 1995 Oct; 275(1):285-95. PubMed ID: 7562561
[TBL] [Abstract][Full Text] [Related]
15. Activation of neuromedin B-preferring bombesin receptors on rat glioblastoma C-6 cells increases cellular Ca2+ and phosphoinositides.
Wang LH; Battey JF; Wada E; Lin JT; Mantey S; Coy DH; Jensen RT
Biochem J; 1992 Sep; 286 ( Pt 2)(Pt 2):641-8. PubMed ID: 1326946
[TBL] [Abstract][Full Text] [Related]
16. Systematic development of bombesin/gastrin-releasing peptide antagonists.
Coy DH; Jensen RT; Jiang NY; Lin JT; Bogden AE; Moreau JP
J Natl Cancer Inst Monogr; 1992; (13):133-9. PubMed ID: 1389686
[TBL] [Abstract][Full Text] [Related]
17. Specific binding and growth effects of bombesin-related peptides on mouse colon cancer cells in vitro.
Narayan S; Guo YS; Townsend CM; Singh P
Cancer Res; 1990 Nov; 50(21):6772-8. PubMed ID: 2208141
[TBL] [Abstract][Full Text] [Related]
18. Differential activation of human gastrin-releasing peptide receptor-mediated responses by bombesin analogs.
Wu JM; Hoang DO; Feldman RI
Mol Pharmacol; 1995 Apr; 47(4):871-81. PubMed ID: 7723750
[TBL] [Abstract][Full Text] [Related]
19. A synthetic glycine-extended bombesin analogue interacts with the GRP/bombesin receptor.
Oiry C; Pannequin J; Bernad N; Artis AM; Galleyrand JC; Devin C; Cristau M; Fehrentz JA; Martinez J
Eur J Pharmacol; 2000 Sep; 403(1-2):17-25. PubMed ID: 10969139
[TBL] [Abstract][Full Text] [Related]
20. N-isobutyryl-His-Trp-Ala-Val-D-Ala-His-Leu-NHMe (ICI 216140) a potent in vivo antaconist analogue of bombesin/gastrin releasing peptide (BN/GRP) derived from the C-terminal sequence lacking the final methionine residue.
Camble R; Cotton R; Dutta AS; Garner A; Hayward CF; Moore VE; Scholes PB
Life Sci; 1989; 45(17):1521-7. PubMed ID: 2555638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
